MiNK Therapeutics, Inc. (INKT)
11.84
+0.39
(+3.41%)
USD |
NASDAQ |
Sep 09, 16:00
11.84
0.00 (0.00%)
After-Hours: 17:45
MiNK Therapeutics Enterprise Value : 49.55M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 49.55M |
| September 04, 2026 | 50.52M |
| September 03, 2026 | 48.43M |
| September 02, 2026 | 48.94M |
| September 01, 2026 | 47.00M |
| August 31, 2026 | 47.72M |
| August 28, 2026 | 49.44M |
| August 27, 2026 | 50.72M |
| August 26, 2026 | 51.28M |
| August 25, 2026 | 49.19M |
| August 24, 2026 | 51.44M |
| August 21, 2026 | 53.37M |
| August 20, 2026 | 50.42M |
| August 19, 2026 | 47.92M |
| August 18, 2026 | 52.35M |
| August 17, 2026 | 48.38M |
| August 14, 2026 | 48.63M |
| August 13, 2026 | 47.26M |
| August 12, 2026 | 49.09M |
| August 11, 2026 | 48.43M |
| August 10, 2026 | 47.00M |
| August 07, 2026 | 47.00M |
| August 06, 2026 | 47.26M |
| August 05, 2026 | 50.82M |
| August 04, 2026 | 47.61M |
| Date | Value |
|---|---|
| August 03, 2026 | 45.68M |
| July 31, 2026 | 44.71M |
| July 30, 2026 | 45.17M |
| July 29, 2026 | 44.10M |
| July 28, 2026 | 44.91M |
| July 27, 2026 | 45.17M |
| July 24, 2026 | 47.61M |
| July 23, 2026 | 43.99M |
| July 22, 2026 | 43.38M |
| July 21, 2026 | 47.61M |
| July 20, 2026 | 46.08M |
| July 17, 2026 | 45.52M |
| July 16, 2026 | 46.29M |
| July 15, 2026 | 47.72M |
| July 14, 2026 | 49.35M |
| July 13, 2026 | 48.02M |
| July 10, 2026 | 47.51M |
| July 09, 2026 | 49.60M |
| July 08, 2026 | 44.96M |
| July 07, 2026 | 45.32M |
| July 06, 2026 | 50.11M |
| July 02, 2026 | 50.67M |
| July 01, 2026 | 49.60M |
| June 30, 2026 | 50.77M |
| June 29, 2026 | 49.65M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
| Vericel Corp. | 1.932B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.128M |
| Total Expenses (Quarterly) | 3.128M |
| EPS Diluted (Quarterly) | -0.6227 |
| Earnings Yield | -20.25% |
| Normalized Earnings Yield | -20.71 |